ANDA 76578, held by Rising. Zolpidem Tartrate.
As of Nov 16, 2026, ANDA 76578 (Zolpidem Tartrate), held by Rising, was first approved by FDA on Apr 23, 2007, with 11 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 23, 2007 | Original application | Approved |
| Zolpidem Tartrate5MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Zolpidem Tartrate10MG · tablet;oral | Zolpidem Tartrate | Discontinued |
| Nov 21, 2022 | Supplement 21Labeling · Standard review | Approved | None posted |
| Oct 25, 2019 | Supplement 13Labeling · Standard review | Approved | None posted |
| Oct 25, 2019 | Supplement 14Labeling · Standard review | Approved | None posted |
| Oct 25, 2019 | Supplement 15Labeling · Standard review | Approved | None posted |
| Oct 25, 2019 | Supplement 17Labeling · Standard review | Approved | None posted |
| Oct 25, 2019 | Supplement 18Labeling · Standard review | Approved | None posted |
| Oct 25, 2019 | Supplement 19Labeling · Standard review | Approved | None posted |
| Mar 19, 2015 | Supplement 12Labeling · Standard review | Approved | None posted |
| Mar 31, 2014 | Supplement 11Labeling · Standard review | Approved | None posted |
| Jan 21, 2011 | Supplement 8Labeling | Approved | None posted |
| Nov 19, 2008 | Supplement 4Labeling | Approved | None posted |
| Apr 23, 2007 | Original application | Approved |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters